Orikine Bio SL, a developer of precision immunotherapies, has appointed Larry Edwards chairman of the board. He brings more than 20 years’ pharma industry experience, notably in M&A, financing and building net cash positive companies. Mr Edwards is chief executive officer of AiCuris, and previously he was CEO of La Jolla Pharmaceutical Company. Orikine Bio was founded in 2022 as a spin-off from the Centre for Genomic Regulation in Barcelona, Spain. It closed a €5.5 million seed financing round and obtained €2.8 million in non-dilutive government grant funding in 2023. The company is accelerating the preclinical development of its immunotherapy programmes and progressing towards clinical and corporate milestones.
Orikine Bio announced the appointment on 20 January 2026.
Copyright 2026 Evernow Publishing Ltd.